奈达铂联合多西他赛治疗晚期非小细胞肺癌对于T淋巴细胞亚群的影响

目的：研究奈达铂联合多西他赛治疗晚期非小细胞肺癌患者对于其T淋巴细胞亚群的影响。方法：选取93例晚期非小细胞肺癌患者，随机分为研究组47例及对照组46例。分别接受奈达铂联合多西他赛治疗和顺铂联合紫杉醇治疗。比较两组近期疗效及T淋巴细胞亚群水平。结果：研究组完全缓解（CR）率高于对照组，部分缓解（PR）率低于对照组，差异具有统计学意义（P〈0．05）。研究组治疗后T淋巴细胞亚群水平与治疗前比较，差异无统计学意义（P〉0．05）。对照组治疗后的NK、CD3、以及CD4／CD8水平均低于治疗前，CD8水平高于治疗前，CD4水平与治疗前相比，差异无统计学意义（P〉0．05）。研究组NK、CD3、以及CD4／cD8水平均高于对照组，CD8水平低于对照组，CD4水平两组比较，差异无统计学意义（P〉0．05）。结论：奈达铂联合多西他赛治疗晚期非小细胞肺癌疗效肯定，且对于患者T淋巴细胞亚群水平的影响较小，值得推荐。

Effect of nedaplatin plus docetaxel on T lymphocyte subsets in patients with advanced non- small cell lung cancer

Objective： To study patients with advanced non-small cell vanced NSCLC were randomly divided treated with nedaplatin plus doeetaxel short-term effects and T lymphocyte su the effect of nedaplatin cancer （NSCLC）. plus docetaxel on T lymphocyte subsets in Methods： Ninety-three patients with ad- into research group （n=47） and control group （n=46） which were and control group and cisplatin plus paclitaxel respectively. The bset levels of two groups were compared. Results. CR rate was significantly higher, but PD rate was obviously lower in research group than in control group. There was no significant difference in research group compared with T lymphocyte subset level after treatment with that before treatment. After treatment, the levels of NK, CD3 and CD4/CD8 in reseraeh group were markedly higher, but CD8 level was lower than that in the control group. No significant in CD4 level was found be- tween the two groups （P〈0.05）. Conclusion： Nedaplatin plus docetaxel shows definite efficiency on ad- vanced NSCLC, and exerts minor influence on T lymphocyte subset level, hence the treatment deserves to be recommended.